Page 116 - 《中国药房》2021年12期

et al. Nivolumab plus ipilimumab in lung cancer with a center phase Ⅱ study[J]. J Clin Oncol，2012，30（17）：
high tumor mutational burden[J]. N Engl J Med，2018，378 2046-2054.
（22）：2093-2104. [32] WEST H，MCCLEOD M，HUSSEIN M，et al. Atezolizu-
[24] RIZVI N A，CHO B C，REINMUTH N，et al. Durvalumab mab in combination with carboplatin plus nab-paclitaxel
with or without tremelimumab vs standard chemotherapy chemotherapy compared with chemotherapy alone as
in first-line treatment of metastatic non-small cell lung first-line treatment for metastatic non-squamous non-
cancer：the mystic phase 3 randomized clinical trial[J]. small-cell lung cancer（IMpower130）：a multicentre，ran-
JAMA Oncology，2020，6（5）：661-674. domised，open-label，phase 3 trial[J]. Lancet Oncol，2019，
[25] PAZ-ARES L，VICENTE D，TAFRESHI A，et al. A ran- 20（7）：924-937.
domized，placebo-controlled trial of pembrolizumab plus [33] JOTTE R，CAPPUZZO F，VYNNYCHENKO I，et al.
chemotherapy in patients with metastatic squamous non- Atezolizumab in combination with carboplatin and nab-pa-
small-cell lung cancer：protocol-specified final analysis of
clitaxel in advanced squamous NSCLC（IMpower131）：re-
keynote-407[J]. J Thorac Oncol，2020，15（10）：1657-
sults from a randomized phase Ⅲ trial[J]. J Thorac Oncol，
1669.
2020，15（8）：1351-1360.
[26] GANDHI L，RODRÍGUEZ-ABREU D，GADGEEL S，et al.
[34] GONG J，CHEHRAZI-RAFFLE A，REDDI S，et al. De-
Pembrolizumab plus chemotherapy in metastatic non-
velopment of PD-1 and PD-L1 inhibitors as a form of can-
small-cell lung cancer[J]. N Engl J Med，2018，378（22）：
cer immunotherapy：a comprehensive review of registra-
2078-2092.
tion trials and future considerations[J]. J Immunother Can-
[27] LANGER C J，GADGEEL S M，BORGHAEI H，et al.
cer，2018，6（1）：8-26.
Carboplatin and pemetrexed with or without pembrolizu-
[35] SAIGI M，ALBURQUERQUE-BEJAR J J，SANCHEZ-
mab for advanced，non-squamous non-small-cell lung can-
CESPEDES M. Determinants of immunological evasion
cer：a randomised，phase 2 cohort of the open-label key-
and immunocheckpoint inhibition response in non-small
note-021 study[J]. Lancet Oncol，2016，17（11）：1497-
cell lung cancer：the genetic front[J]. Oncogene，2019，38
1508.
（31）：5921-5932.
[28] GOVINDAN R，SZCZESNA A，AHN M J，et al. Phase Ⅲ
[36] LIN L L，LIN G F，LUO Q，et al. The incidence and rela-
trial of ipilimumab combined with paclitaxel and carbopla-
tive risk of PD-1/PD-L1 inhibitors-related colitis in non-
tin in advanced squamous non-small-cell lung cancer[J]. J
Clin Oncol，2017，35（30）：3449-3457. small cell lung cancer：a meta-analysis of randomized con-
[29] HELLMANN M D，PAZ-ARES L，BERNABE CARO R， trolled trials[J]. Int Immunopharmacol，2019，77：105975.
et al. Nivolumab plus ipilimumab in advanced non-small- [37] ELTOBGY M，OWEIRA H，PETRAUSCH U，et al. Im-
cell lung cancer[J]. N Engl J Med，2019，381（21）：2020- mune-related neurological toxicities among solid tumor
2031. patients treated with immune checkpoint inhibitors：a sys-
[30] SOCINSKI M A，JOTTE R M，CAPPUZZO F，et al. tematic review[J]. Expert Rev Neurother，2017，17（7）：
Atezolizumab for first-line treatment of metastatic non- 725-736.
squamous NSCLC[J]. N Engl J Med，2018，378（24）： [38] WANG D Y，SALEM J E，COHEN J V，et al. Fatal toxic
2288-2301. effects associated with immune checkpoint inhibitors：a
[31] LYNCH T J，BONDARENKO I，LUFT A，et al. Ipilimu- systematic review and meta-analysis[J]. JAMA Oncol，
mab in combination with paclitaxel and carboplatin as 2018，4（12）：1721-1728.
first-line treatment in stage Ⅲ B/Ⅳ non-small-cell lung （收稿日期：2021-01-27 修回日期：2021-05-05）
cancer：results from a randomized，double-blind，multi- （编辑：陈 宏）

·1514 · China Pharmacy 2021 Vol. 32 No. 12 中国药房 2021年第32卷第12期